Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Ines Pires da Silva, Tasnia Ahmed, Irene L.M. Reijers, Alison M. Weppler, Allison Betof Warner, James Randall Patrinely, Patricio Serra-Bellver, Clara Allayous, Joanna Mangana, Khang Nguyen, Lisa Zimmer, Claudia Trojaniello, Dan Stout, Megan Lyle, Oliver Klein, Camille L. Gerard, Olivier Michielin, Andrew Haydon, Paolo A. Ascierto, Matteo S. CarlinoCeleste Lebbe, Paul Lorigan, Douglas B. Johnson, Shahneen Sandhu, Serigne N. Lo, Christian U. Blank, Alexander M. Menzies, Georgina V. Long

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study'. Together they form a unique fingerprint.

Medicine & Life Sciences